newsfilter
← Latest News
Business Wire·

Infinity Pharmaceuticals to Host an Investor Event on Updated MARIO-3 Data Presented at the 2021 San Antonio Breast Cancer Symposium

MARIO-3 Phase 2 study evaluating eganelisib added to standard of care Tecentriq® and Abraxane® regimen in frontline triple negative breast cancer (TNBC) Investor Event with KOL Scheduled for Friday, December 10th @ 9:30am ET Infinity Pharmaceu